Fibromyalgia
A chronic disorder causing widespread body pain, severe fatigue, and brain fog, stemming from how the brain processes pain.
Emergency Management: Suicidal ideation due to severe, unmanaged chronic pain and comorbid depression.
Fibromyalgia is a chronic, non-inflammatory central pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. It arises from dysregulation in the central nervous system's processing of pain signals rather than tissue damage.
Detailed Overview
Patients with fibromyalgia experience a heightened state of pain sensitivity (central sensitization). They lack objective signs of inflammation or joint damage on physical exam or imaging, which often leads to misdiagnosis or skepticism. It frequently co-occurs with other central sensitivity syndromes like irritable bowel syndrome (IBS) and chronic headaches. Management requires a multidisciplinary approach focusing on exercise, cognitive behavioral therapy, and neuro-modulating medications.
Epidemiology & Demographics
Affects 2-8% of the global population. Highly female predominant (female-to-male ratio is roughly 2:1 to 3:1). Usually diagnosed between ages 20 and 55.
Etiological Mechanism
The exact cause is unknown. It is believed to be triggered by physical trauma, severe psychological stress, or viral infections in genetically susceptible individuals.
Primary Causes
Idiopathic central nervous system dysfunction. Triggers include emotional trauma, PTSD, MVCs, or illnesses like Epstein-Barr Virus.
The core mechanism is "central sensitization" of the nervous system. There is an amplification of nociceptive (pain) signals and a deficit in descending inhibitory pain pathways (which normally utilize serotonin and norepinephrine to blunt pain). Functional MRI studies show hyperactivity in the somatosensory cortex and insula in response to non-painful stimuli (allodynia). Elevated levels of Substance P and glutamate in the cerebrospinal fluid enhance pain signal transmission. The lack of restorative slow-wave sleep prevents normal tissue recovery and exacerbates fatigue and pain.
Diagnostic Criteria & Guidelines
ACR 2016 criteria: Widespread Pain Index (WPI) >= 7 and Symptom Severity (SS) scale >= 5, OR WPI 4-6 and SS >= 9. Symptoms must be present at a similar level for at least 3 months, without another disorder explaining the pain.
Non-pharmacologic: Graded aerobic exercise (the most effective treatment) and Cognitive Behavioral Therapy (CBT). Pharmacologic: SNRIs like Duloxetine (30-60 mg PO daily) or Milnacipran (50 mg PO BID) to boost descending inhibitory pathways, or Gabapentinoids like Pregabalin (75-150 mg PO BID) to reduce neurotransmitter release.
Second-Line & Adjunctive Therapy
Tricyclic antidepressants: Amitriptyline 10-25 mg PO QHS to improve sleep architecture and pain. Cyclobenzaprine 5-10 mg PO QHS for muscle spasm/sleep. (Note: NSAIDs, acetaminophen, and opioids are generally ineffective and not recommended).
Surgical & Procedural Management
Not applicable. Surgery often acutely exacerbates fibromyalgia symptoms.
Patient Counseling & Advice
Validate the patient's illness; assure them the pain is real but not destructive to their joints or organs. Emphasize that passive treatments (pills, massages) are less effective than active treatments (exercise, CBT).
Follow-Up & Monitoring Schedule
Follow up every 3 months initially to titrate medications and assess adherence to exercise programs. Monitor for emergence of clinical depression.
Preventive Strategies
No proven primary prevention. Early intervention after physical/emotional trauma may reduce the risk of developing centralized pain.
Chronic and fluctuating course. It is not life-threatening and does not cause physical deformity. Most patients adapt and maintain function with multidisciplinary management, though true "cure" is rare.